RWE is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of Real-World Data (RWD), including EHRs, registries, and claims. FDA's 2017 guidance on using RWE for device decisions says RWD can support new indications, post-approval studies and even primary approval evidence when it is relevant and reliable. Fitness for purpose depends on data provenance, completeness, and how well confounding is addressed. Registries such as the TVT Registry are frequently cited examples.

Why it matters

FDA accepts RWE to support regulatory decisions when relevance and reliability are demonstrated. RWE is increasingly important for AI/ML monitoring and PMS.

Common pitfalls

•RWE derived from unreliable or biased RWD sources may not be accepted by regulatory authorities, leading to delays or rejection of submissions.
•Failure to adequately document RWD collection methods and RWE analysis plans can undermine the credibility of the evidence.
•Generalizing RWE from one population to another without proper justification is a common pitfall.
•Ignoring potential confounding factors in RWD can lead to inaccurate conclusions about a medical product's performance.
•Using RWE for indications not supported by the data's scope or context will be viewed critically by regulators, such as the FDA.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.